证券代码：688626 证券简称：翔宇医疗 公告编号：2025-030 河南翔宇医疗设备股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 15 日 （二） 股东大会召开的地点：河南省安阳市内黄县帝喾大道中段公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 33 | | --- | --- | | 普通股股东人数 | 33 | | 2、出席会议的股东所持有的表决权数量 | 120,829,326 | | 普通股股东所持有表决权数量 | 120,829,326 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 78.3654 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 78.3654 | 注：公司表决权数 ...

SHANGHAI 19F ONE LUJIAZUL 8 Yin Chena Road Middle hanahai 200120 PR China 上海市通力律师事务所 关于河南翔宇医疗设备股份有限公司 2024 年年度股东大会的法律意见书 致:河南翔宇医疗设备股份有限公司 上海市通力律师事务所(以下简称"本所")接受河南翔宇医疗设备股份有限公司(以下 简称"公司")的委托,指派本所黄雅程律师、赵伯晓律师(以下简称"本所律师")根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和规 范性文件(以下统称"法律法规")及《河南翔宇医疗设备股份有限公司章程》(以下简称"公 司章程")的规定就公司 2024 年年度股东大会(以下简称"本次股东大会")相关事宜出具 法律意见。 本所及本所律师依据法律法规及本法律意见出具目以前已经发生或者存在的事实,严 格履行了法定职责,遵循了勤勉尽责和诚实信用原则,进行了充分的核查验证,保证本法律 意见所认定的事实真实、准确、完整,所发表的结论性意见合法、准确,不存在虚假记载、 误导性陈述或者重大遗漏,并承担相应法律责任。 24BJ7200117/S ...

国泰海通证券股份有限公司 关于河南翔宇医疗设备股份有限公司 2024 年度持续督导年度跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：翔宇医疗 | | --- | --- | | 保荐代表人姓名：刘君、岑平一 | 被保荐公司代码：688626.SH | 重大事项提示 经中国证券监督管理委员会《关于同意河南翔宇医疗设备股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕254 号）批复，河南翔宇医疗设 备股份有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发 行股票 40,000,000 股，每股面值人民币 1 元，每股发行价格人民币 28.82 元，募 集资金总额为人民币 1,152,800,000.00 元，扣除发行费用后，实际募集资金净额 为人民币 1,049,656,554.20 元。本次发行证券已于 2021 年 3 月 31 日在上海证券 交易所上市。国泰海通证券股份有限公司（以下简称"保荐机构"或"国泰海通"） 担任其持续督导保荐机构，持续督导期间为 2021 年 3 月 31 日至 2024 年 12 月 31 日。 在 2024 年 1 月 ...

国泰海通证券股份有限公司关于河南翔宇医疗设备股份有限公司 首次公开发行股票并上市 之保荐总结报告书 | 保荐机构名称： | 国泰海通证券股份有限公司 | | --- | --- | | 保荐机构编号： | Z29131000 | 经中国证券监督管理委员会《关于同意河南翔宇医疗设备股份有限公司首次公 开发行股票注册的批复》（证监许可〔2021〕254 号）批复，河南翔宇医疗设备股份 有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发行股票 40,000,000 股，每股面值人民币 1 元，每股发行价格人民币 28.82 元，募集资金总额为人民币 1,152,800,000.00 元，扣除发行费用后，实际募集资金净额为人民币 1,049,656,554.20 元。本次发行证券已于 2021 年 3 月 31 日在上海证券交易所科创板上市。原海通证 券股份有限公司担任其持续督导保荐机构，持续督导期间为 2021 年 3 月 31 日至 2024 年 12 月 31 日。鉴于原国泰君安证券股份有限公司换股吸收合并原海通证券股 份有限公司事项已获得中国证券监督管理委员会核准批复，本次合并交易已于 2025 ...

Group 1: Company Overview - Chengquan Capital recently conducted research on Xiangyu Medical, revealing a projected net profit of 102.94 million yuan for 2024, a decrease of 54.68% year-on-year [1] - For Q1 2025, Xiangyu Medical's net profit is expected to be 22.95 million yuan, reflecting a year-on-year decrease of 41.26% [1] - Xiangyu Medical focuses on the "big rehabilitation" sector, emphasizing the development of rehabilitation robots and brain-machine interface products [1] Group 2: Product Development and Market Position - The portable exoskeleton assistive robot has entered the small batch production phase, with expectations to obtain medical device registration and launch sales within the year [1] - The rehabilitation industry is experiencing a continuous increase in product variety and significant improvements in technology, establishing it as a rapidly growing sector with strong market demand [1] - Xiangyu Medical's transcranial magnetic therapy robot addresses challenges such as target localization and treatment accuracy [1] Group 3: Technological Advantages - The company possesses advantages in brain-machine interface technology, including proprietary core algorithms and self-developed data collection devices [1] - In the short term, the exoskeleton robot will primarily serve medical applications, while in the medium to long term, the company plans to develop home-use versions [1] - The rehabilitation exoskeleton robot enables high-intensity, high-repetition rehabilitation training, providing objective assessment data and reducing reliance on advanced therapists [1] Group 4: Future Innovations - Xiangyu Medical is developing products that combine brain-machine interfaces with exoskeleton robots for rehabilitation training of patients with weakened lower limb strength [1]

河南翔宇医疗设备股份有限公司 2024 年年度股东大会会议资料 证券代码：688626 证券简称：翔宇医疗 河南翔宇医疗设备股份有限公司 2024 年年度股东大会 会议资料 2025 年 5 月 1 河南翔宇医疗设备股份有限公司 2024 年年度股东大会会议资料 河南翔宇医疗设备股份有限公司 2024 年年度股东大会会议资料目录 | 2024 | 年年度股东大会会议须知 | 3 | | | | --- | --- | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | 6 | | | | 2024 | 年年度股东大会会议议案 | 8 | | | | 议案 | 1：关于公司 2024 | 年度董事会工作报告的议案 | | 8 | | 议案 | 2：关于公司 2024 | 年度监事会工作报告的议案 | | 16 | | 议案 | 3：关于公司 2024 | 年年度报告及其摘要的议案 | | 21 | | 议案 | 4：关于公司 2024 | 年度财务决算报告的议案 | | 22 | | 议案 | 5：关于公司 2024 | 年年度利润分配方案的议案 | | 26 | | 议案 | 6 ...

Investment Rating - Investment rating: Buy (maintained) [2][8] Core Views - The company is facing short-term pressure on performance in 2024, but is increasing R&D investment to build long-term advantages [2][6] - The company reported a revenue of 744 million yuan in 2024, a slight decrease of 0.17% year-on-year, and a net profit attributable to shareholders of 103 million yuan, down 54.68% year-on-year [6][9] - The company is focusing on the rehabilitation sector, which has significant long-term potential, while experiencing short-term profit pressure due to rising expense ratios [6][9] Financial Performance Summary - 2024 revenue: 744 million yuan (yoy -0.17%); net profit: 103 million yuan (yoy -54.68%); non-recurring net profit: 89.97 million yuan (yoy -55.90%) [6][11] - Q4 2024 revenue: 237 million yuan (yoy +16.74%); net profit: 29.53 million yuan (yoy -38.45%); non-recurring net profit: 25.54 million yuan (yoy -35.06%) [6][11] - Q1 2025 revenue: 186 million yuan (yoy +10.02%); net profit: 22.95 million yuan (yoy -41.26%); non-recurring net profit: 18.71 million yuan (yoy -48.72%) [6][11] Expense and Profitability Metrics - Sales expense ratio: 28.91% (yoy +6.10pct); management expense ratio: 8.10% (yoy +2.60pct); R&D expense ratio: 20.45% (yoy +6.12pct) [6][9] - Gross margin: 67.42%, down 1.20 pct year-on-year; net margin: 13.83%, down 16.82 pct year-on-year [6][9] R&D Investment and Future Outlook - R&D investment in 2024 was 152 million yuan, an increase of 42.41% year-on-year, accounting for 20.45% of total revenue [6][9] - The company has established multiple R&D centers and is focusing on advanced technologies such as brain-machine interfaces and rehabilitation robotics [7][9] - Revenue projections for 2025-2027 are 848 million yuan, 972 million yuan, and 1.121 billion yuan, with growth rates of 14.1%, 14.6%, and 15.3% respectively [8][11] Earnings Per Share and Valuation - Expected EPS for 2025-2027: 0.94 yuan, 1.21 yuan, and 1.57 yuan, with corresponding P/E ratios of 38x, 29x, and 23x [9][11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][8] Core Views - The company's performance is under short-term pressure in 2024, but increased R&D investment is expected to build long-term advantages [2][6] - The company reported a revenue of 744 million yuan in 2024, a year-on-year decrease of 0.17%, and a net profit attributable to shareholders of 103 million yuan, down 54.68% year-on-year [6][9] - The company is focusing on the rehabilitation sector, which has significant long-term potential despite short-term profit pressures due to rising expense ratios [6][9] Financial Performance Summary - In 2024, the company achieved a revenue of 744 million yuan, with a year-on-year change of -0.17% [6][11] - The net profit attributable to shareholders was 103 million yuan, reflecting a year-on-year decline of 54.68% [6][11] - The company’s gross margin was 67.42%, down 1.20 percentage points year-on-year, and the net margin was 13.83%, down 16.82 percentage points year-on-year [6][11] - R&D expenses increased by 42.41% year-on-year to 152 million yuan, representing 20.45% of total revenue [6][11] Revenue Breakdown - Revenue from rehabilitation therapy equipment was 504 million yuan, up 9.85% year-on-year [6][9] - Revenue from rehabilitation training equipment was 165 million yuan, down 19.89% year-on-year [6][9] - Revenue from rehabilitation assessment equipment was 27.62 million yuan, down 21.92% year-on-year [6][9] Future Projections - Revenue projections for 2025, 2026, and 2027 are 848 million yuan, 972 million yuan, and 1.121 billion yuan, respectively, with growth rates of 14.1%, 14.6%, and 15.3% [8][11] - Net profit projections for the same years are 151 million yuan, 194 million yuan, and 251 million yuan, with growth rates of 46.5%, 28.8%, and 29.3% [8][11] - The expected EPS for 2025, 2026, and 2027 are 0.94 yuan, 1.21 yuan, and 1.57 yuan, respectively [8][11]

Group 1 - The core products of Zhaoli Pharmaceutical show stable growth, with a high dividend payout ratio maintained, achieving a revenue of 2.578 billion yuan in 2024, a year-on-year increase of 32.71% [8][9] - The company has significantly reduced costs and improved efficiency, with a notable decrease in expense ratios, including a sales expense ratio of 32.53%, down 7.5 percentage points year-on-year [9] - The company plans to implement an employee stock ownership plan by the end of 2024, with profit growth targets set at no less than 30% for 2025 [10] Group 2 - Weining Health's revenue for Q1 2025 was 345 million yuan, a year-on-year decrease of 30.24%, with a net profit of 5.29 million yuan, down 68.18% [11][12] - The company is focusing on cost reduction and efficiency improvement, with a significant increase in cash flow from operating activities, up 120.53% year-on-year [12] - The WiNEX product is entering a phase of mass delivery, supporting internet operations and international adaptation, with a strong digital architecture capable of handling millions of transactions [14][15] Group 3 - Lais Information's revenue for 2024 was 1.61 billion yuan, a year-on-year decrease of 3.94%, while Q1 2025 revenue dropped by 55.53% to 109 million yuan [17][18] - The company is optimizing its business structure, with significant growth in air traffic control and urban traffic management sectors, achieving revenue increases of 13.68% and 33.47% respectively [18][19] - The company is enhancing its research and development efforts, with a focus on refining its product offerings and improving operational efficiency [20] Group 4 - FenJung Media reported a revenue of 12.262 billion yuan in 2024, a year-on-year increase of 3.01%, with a net profit of 5.155 billion yuan, up 6.80% [23][25] - The company maintains a high dividend payout ratio, with cash dividends amounting to 4.766 billion yuan, representing 92.45% of net profit [24][25] - The planned acquisition of New潮传媒 is expected to enhance the company's competitive position in the outdoor advertising market [28] Group 5 - Jingwang Electronics achieved a revenue of 12.659 billion yuan in 2024, a year-on-year increase of 17.68%, with a net profit of 1.169 billion yuan, up 24.86% [30][31] - The company is expanding its production capacity, with a focus on high-end markets and AI applications, particularly in the automotive sector [32][33] - The company is increasing its R&D investments to support technological advancements and market expansion [33]

Group 1 - The A-share brain-computer interface sector experienced an initial rise, with Aipeng Medical increasing by over 8% [1] - Chengyitong, Rongtai Health, and Xiangyu Medical all saw increases of over 5% [1] - Companies such as Dineike and Sanbo Neuroscience also followed the upward trend [1]